Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Slides:



Advertisements
Similar presentations
Hot Topics in Antibiotic Management of Pediatric CF Lung Disease Mike Tracy, MD Fellow, Pediatric Pulmonary.
Advertisements

Applying the New Multiple Sclerosis Guidelines to Clinical Practice
Pseudomonas Infection in Cystic Fibrosis
Chronic Hepatitis C Virus Infection
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Treatment Strategies in Mild to Moderate COPD
Starting Strong: Initial Evaluation of the Patient With HCV
Gout Management.
Optimizing Outcomes in Short Bowel Syndrome With IF
Pseudomonas Lung Infections in Cystic Fibrosis
UNDERSTANDING RISK STRATIFICATION IN PAH:
COPD Management.
The HCV Revolution: Are You and Your Practice Ready?
Clinical Review.
Stepping Up Asthma Control for Effective Management
Medication Nonadherence in Gout
Advances in Cystic Fibrosis 2017
SGLT2 Inhibitors in the Modern Era: Why and Where?
Clinical Cases in Glaucoma Treatment
An Interprofessional Approach to the Patient With Chronic Airway Disease.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016.
When Would You Use Single Inhaler Triple Therapy in COPD?
Combination Inhaled Therapy in COPD: The Impact of Recent Data
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.
Advances in Cystic Fibrosis Perspectives From Orlando, 2016
HCV Protease Inhibitors in Clinical Practice
Postpartum Depression
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Program Overview. Treatment Options for Post-MI patients with LVD – are all ACE Inhibitors Equal?
Implementing Best Practices in the Management of Allergic Diseases
Evaluating Effects of CFTR Modulation in Cystic Fibrosis
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
Demographics of IPF in the USa-d
Biotherapeutics.
Maternal Pertussis vaccination: Giving Newborns a head start
The Road to Quality Improvement in HER2-Positive Breast Cancer
Understanding and Addressing the Needs of Patients With AD
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Treatment-Resistant Schizophrenia
New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014
Atopic Dermatitis in the Pediatric Practice
Implications of Emerging Treatments for Beta-Thalassemia
Managing Age-Related Clinical Issues in Hemophilia
A Guideline-Based Approach to HCV Care
HCV Protease Inhibitors in Clinical Practice
Are We Making Progress in the Management of Huntington Disease?
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
Controlling Elevated Blood Pressure
Addressing Treatment Challenges in Cystic Fibrosis
Clinical Challenges and Updates in Managing Seizure Clusters
Assessing the Burden of Hyperkalemia
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Strategies for Infection Control in Cystic Fibrosis
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
Assessing the Burden of Hyperkalemia
Rational Pharmacotherapy Selection for Insomnia
PAH Pathways: What Do the Data Tell Us?”
Clinical Comparisons in CTEPH
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Minimal Residual Disease and Hematologic Malignancies
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Targeted Care for COPD.
The Asthma Treatment Gap
Navigating the Journey
Presentation transcript:

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Program Overview

Treatment Goals in CF

Prevalence of Pulmonary Infection in Children and Adolescents With CF

Prevalence of Pulmonary Infection in Adults With CF

Emerging Infections in CF

CFTR Dysfunction, Chronic Infection, and Disease Progression

Targeting the Airway Microenvironment With Inhaled Antibiotics

Managing Chronic P aeruginosa Infection

Considerations in Managing Chronic P aeruginosa Infection in Children

Pulmonary Exacerbations

Delivery of Inhaled Antibiotics

Challenges of Eradicating P aeruginosa in Children

Inhaled Antibiotics Targeting P aeruginosa

Inhaled Antibiotic Therapy: Guideline Recommendations

Continuous Alternating Therapy: Rationale

CAT Study: Design

CAT Study: Results

Using CAT in Clinical Practice

Maximizing Delivery of Inhaled Antibiotics

Predictors of Adherence to Inhaled Antibiotics

Rates of Adherence to CF Therapies

Effects of Therapy Adherence on Exacerbations

Using Inhaled Antibiotics Alongside CFTR Modulators

Potential Impact of CFTR Modulators on the Microbiome

Conclusions

Abbreviations

Abbreviations (cont)